SecBot SecBot

CRBU drug pipeline

Caribou Biosciences, Inc. · 2 rated drugs
$0.3530
−2.5% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±15.7%
1-day, median of 5 events
IV rank
No data
No current options data
Rated drugs
2
2 bearish
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▼ bearish
Impact
PhasePhase 1 (discontinued)
Time to marketNot applicable. CB-011 development has been discontinued and the program terminated (Oct 2026).

CB-011 Updated Nov 8

What to watch

CB-011 development has been discontinued. The next event is the ASH 2026 presentation (Dec 12-15), but it is a look-back on a terminated program. The real stock-moving catalyst is the strategic alternatives process (potential sale/merger of Caribou), which has no announced timeline. Watch for any acquisition or asset-sale announcement from the company's exploration process.

Bull case
  • CB-011 generated strong Phase 1 data: 92% ORR, 75% CR rate, and 91% MRD negativity in BCMA-naive patients at the recommended dose (Nov 2025 data).
  • Updated EHA 2026 data showed 83% CR rate and 50% of patients in CR at 15 months, suggesting durability.
  • CB-011 received both FDA Fast Track designation (Apr 2023) and RMAT designation (Mar 2026), signaling regulatory interest.
Bear case
  • CB-011 development has been permanently discontinued (Oct 2026), eliminating any future upside from the drug itself.
  • Caribou is exploring strategic alternatives including a potential sale, indicating the company could not secure funding to advance its pipeline.
  • Multiple analysts downgraded CRBU after the discontinuation announcement (HC Wainwright to Neutral, RBC to Sector Perform, Leerink to Market Perform, Brookline to Hold).
▼ bearish
Impact
PhasePhase 1 (discontinued)
Time to marketThe program has been discontinued. No path to market exists under Caribou's current plans, though the company is exploring strategic alternatives (sale, merger, or dissolution) that could theoretically see the asset developed by another party.

vispa-cel vispacabtagene regedleucel Updated Nov 8

What to watch

vispa-cel is a discontinued program at a company pursuing a fire sale or dissolution. The ASH presentations December 12-15 are the last scheduled data readouts but come from a halted program. The stock's fate now hinges entirely on the strategic alternatives process (merger, asset sale, or liquidation), not on vispa-cel data. Watch for any definitive agreement announcement from Caribou's advisor Wedbush Securities.

Bull case
  • vispa-cel generated some of the strongest allogeneic CAR-T efficacy data to date, with Phase 1 results showing a median progression-free survival of 17.1 months in second-line large B-cell lymphoma, comparable to approved autologous CAR-T therapies (source: FierceBiotech, June 2026).
  • The FDA granted both Orphan Drug and Fast Track designations for vispa-cel in B-cell non-Hodgkin lymphoma, signaling regulatory interest.
  • Caribou held $94.8M in cash as of September 30, 2026, providing a potential cash buffer for a strategic transaction that could surface value for the vispa-cel asset (source: SEC 8-K filed Nov 5, 2026).
Bear case
  • Caribou has formally discontinued vispa-cel development. The October 6, 2026 announcement halted both clinical programs and initiated a workforce reduction, with the company exploring strategic alternatives including potential dissolution and liquidation (source: SEC 8-K filed Oct 6, 2026).
  • The stock has collapsed approximately 63% since the October 6 announcement, trading around $0.44 with a market cap near $49M, reflecting the market's view that the pipeline has minimal standalone value.
  • Multiple analysts downgraded CRBU in October 2026 (RBC, Leerink, HC Wainwright, Brookline Capital), and the mean price target fell from $7.55 to $5.71, though the stock trades far below even the lowest target.

Past FDA events & how the stock moved

5 events
DateDrugEvent1 day5 days
Oct 6, 2026vispa-celFast Track−48.1%−60.5%
Oct 6, 2026vispa-celOrphan drug designation−48.1%−60.5%
Jun 11, 2026vispa-celFast Track−10.9%−8.4%
Jun 11, 2026vispa-celOrphan drug designation−10.9%−8.4%
Mar 31, 2026CB-011Breakthrough designation+15.7%+13.4%